Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20587395 | 0.90 | AGTR2 (0.48) | HSD11B1OPRM1S1PR1S1PR5 | |
| SCHEMBL3237901 | 0.86 | HSD11B1 (0.44) | HSD11B1L3MBTL1OPRM1S1PR1S1PR5 | |
| SCHEMBL8102406 | 0.78 | HSD11B1 (0.58) | HSD11B1ALDH1A1S1PR1S1PR5 | |
| SCHEMBL8741021 | 0.76 | L3MBTL1 (0.47) | L3MBTL1ATMALDH1A1MAPK1LMNA | |
| SCHEMBL6202941 | 0.75 | FUCA1 (0.60) | ALDH1A1S1PR1S1PR5 | |
| SCHEMBL927653 | 0.75 | HSD11B1 (0.55) | HSD11B1L3MBTL1S1PR1S1PR5 | |
| SCHEMBL10480210 | 0.74 | OPRM1 (0.48) | OPRM1 | |
| SCHEMBL13102888 | 0.74 | L3MBTL1 (0.51) | L3MBTL1ATMALDH1A1LMNACCR8 | |
| SCHEMBL13117075 | 0.74 | L3MBTL1 (0.51) | L3MBTL1ATMALDH1A1LMNACCR8 | |
| SCHEMBL29822372 | 0.73 | GAA (0.40) | L3MBTL1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41439-E1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| WO-2010028011-A1 | AMIDES OF DIAZABICYCLONONANES AND USES THEREOF | TARGACEPT, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| EP-1289996-B1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6852721-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| WO-2001090109-A9 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT INC (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-1289996-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | Targacept, Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6440970-B1 | ACTIVATING NICOTINIC CHOLERGINIC RECEPTORS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001090109-A1 | HETEROARYLDIAZABICYCLOALKANES AS NICOTINIC CHOLINERGIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| US-6153608-A | Isoquinoline derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2000-11-28 | — | — | US | disclosed |
| EP-0885888-A1 | ISOQUINOLINE DERIVATIVES AND DRUGS | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1989000158-A1 | BRIDGED-DIAZABICYCLOALKYL QUINOLONE CARBOXYLIC ACIDS AND ESTERS | PFIZER INC. (US) | 1989-01-12 | — | — | WO | disclosed |
| EP-0297858-A2 | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters | PFIZER INC. (US) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013309-A1 | Pharmaceutical compositions and methods for use | CYP2D6, CYP3A5, CYP2B6 | HSD11B1 858/4885L3MBTL1 4825/4885ATM 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.